Dynamic Monitoring of CTCs and EVs to Predict Chemoimmunotherapy Efficacy in Lung Cancer
Open Access
- 24 September 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2161
Abstract
Background: Circulating tumor cells (CTCs), programmed cell death-ligand 1 (PD-L1) positive CTCs (PD-L1+CTCs) and extracellular vesicles (EVs) are important biomarkers for predicting treatment efficacy. This study comprehensively investigated the factors used to forecast chemoimmunotherapy efficacy in advanced lung cancer. Methods: The CellSearch system, EVAnalyzer plugin and single-cell whole-exome sequencing (WES) were used to analyze these factors. Results: It was found that CTCs were highly detectable in advanced lung cancer. The median number of baseline CTCs was significantly lower in non-small cell lung cancer (NSCLC) than small cell lung cancer (SCLC) (3 vs. 38, p < 0.0001), as were PD-L1+CTCs (1 vs. 5, p = 0.0014). PD-L1+CTCs decreasing after two treatment circles was associated with superior ORR. Baseline median EV counts were elevated in NSCLC compared with SCLC (11,700 vs 1371, p = 0.017). Patients exhibiting divergent dynamic trends between EVs and CTC/PD-L1+CTCs demonstrated better treatment response. The combination of CTCs, PD-L1+CTCs and EVs improved predictive efficacy for both NSCLC and SCLC. CTC sequencing identified multiple pathogenic somatic variants, which might affect immunotherapy efficacy. Conclusions: Serial dynamic monitoring of CTCs, PD-L1+CTCs and EVs, as well as CTC sequencing, enables the early prediction of chemoimmunotherapy response and the discovery of mechanisms that affect immunotherapy efficacy in advanced lung cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81972169)
- Shanghai Municipal Health Commission (2020CXJQ02)
- National Center for Chronic and Noncommunicable Disease Control and Prevention (2024ZD0520206)
- Shanghai Pulmonary Hospital (fkcx2303)
- Shanghai Pulmonary Hospital (fkzr2563)
This publication has 32 references indexed in Scilit:
- Single-cell RNA-sequencing of circulating tumour cells: A practical guide to workflow and translational applicationsCancer and Metastasis Reviews, 2025
- Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trialESMO Open, 2024
- Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumabClinical and Experimental Medicine, 2024
- Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialJournal of Thoracic Oncology, 2023
- EVAnalyzer: High content imaging for rigorous characterisation of single extracellular vesicles using standard laboratory equipment and a new open‐source ImageJ/Fiji pluginJournal of Extracellular Vesicles, 2022
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- Circulating tumor cell isolation for cancer diagnosis and prognosisEBioMedicine, 2022
- Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patientsJournal of Cancer Research and Clinical Oncology, 2022
- PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint InhibitorsClinical Lung Cancer, 2021
- Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survivalBritish Journal of Cancer, 2020